Core Viewpoint - Green Leaf Pharmaceutical (02186) saw a nearly 3% increase in stock price, currently at HKD 3.09, with a trading volume of HKD 8.3751 million, following the announcement of five new products being included in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] Group 1 - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug Catalog [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug Catalog [1]
港股异动 | 绿叶制药(02186)涨近3% 米美欣等五款新品获纳入国家医保药品目录或商保创新药目录